PLUS1
4.74
-0.04 (-0.84%)
-0.04 (-0.84%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Genprex Inc | GNPX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -1.45 | -23.27% | 4.78 | 4.40 | 6.35 | 6.26 | 6.23 | 19:57:42 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.71 | 4.74 | 0.03 | 0.63% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 26,435 | 8,809,915 | $ 5.28 | $ 46,479,031 | 12,732,607 | 0.231 - 7.03 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:28 | 10 | $ 4.74 | USD |
Genprex Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 133.12M | 27.85M | $ -12.37M | -0.89 | - | 27.23M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Genprex News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/21/2020 | 16:15 | Business Wire | Genprex, Inc. Announces Closing of $17,500,000 Common Stock.. |
| 2/20/2020 | 16:33 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 2/19/2020 | 17:31 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 2/19/2020 | 09:23 | Business Wire | Genprex, Inc. Prices $17,500,000 Common Stock Offering.. |
| 2/19/2020 | 08:57 | Edgar (US Regulatory) | Registration of Additional Securities (up to 20%) (s-3mef) |
| 2/19/2020 | 06:05 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/18/2020 | 10:59 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.13 | 7.03 | 3.80 | 5.18 | 12,924,860 | 0.65 | 15.74% |
| 1 Month | 1.57 | 7.03 | 1.17 | 3.72 | 14,096,092 | 3.21 | 204.46% |
| 3 Months | 0.30 | 7.03 | 0.231 | 2.82 | 7,317,338 | 4.48 | 1,493.33% |
| 6 Months | 0.9301 | 7.03 | 0.231 | 2.69 | 3,458,085 | 3.85 | 413.92% |
| 1 Year | 1.43 | 7.03 | 0.231 | 2.67 | 1,791,903 | 3.35 | 234.27% |
| 3 Years | 4.69 | 19.4499 | 0.231 | 3.06 | 1,001,725 | 0.09 | 1.92% |
| 5 Years | 4.69 | 19.4499 | 0.231 | 3.06 | 1,001,725 | 0.09 | 1.92% |
Genprex Description
| Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells. |
